Shattuck Labs Inc
STTK
查看详细走势图
3.770USD
+0.200+5.60%
收盘 02/06, 16:00（美东）报价延迟15分钟
238.08M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+5.60%
5天
-2.58%
1月
-5.28%
6月
+360.43%
今年开始到现在
+3.29%
1年
+204.03%
查看详细走势图
TradingKey Shattuck Labs Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Shattuck Labs Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名104/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.25。中期看，股价处于上升通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Shattuck Labs Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Shattuck Labs Inc亮点
亮点风险
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
业绩高增长
公司营业收入稳步增长，连续3年增长777.45%
业绩增长期
公司处于发展阶段，最新年度总收入5.72M美元
估值低估
公司最新PE估值-3.81，处于3年历史低位
机构加仓
最新机构持股35.95M股，环比增加10.17%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值216.87K
活跃度增加
近期活跃度增加，过去20天平均换手率6.26
分析师目标
根据
7
位分析师
买入
评级
7.250
目标均价
+103.08%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Shattuck Labs Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Shattuck Labs Inc简介
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
公司代码STTK
公司Shattuck Labs Inc
CEOSchreiber (Taylor)
网址https://www.shattucklabs.com/
相关品种
